TRAF6 and myasthenia gravis: Given that reduced TRAF6 expression levels are correlated with improvement in various autoimmune disease models and our results showed a strong relationship between TRAF6 in B cells and disease severity, TRAF6 might be a potential therapeutic target in MG.